Sell-side research often includes analyst views on future stock targets. These analysts will typically also include ratings and estimates in their reports. Investors have the ability to follow analyst projections in order to help compile valuable information. Out of the 6 covering Street analysts offering stock ratings for Epizyme, Inc. (NASDAQ:EPZM), 6 have shares pegged as a Strong Buy while 1 analysts have the stock rated a Buy. 0 analysts have a Hold rating on the stock, and 0 are providing a Sell recommendation.
These recommendations can be transferred to a standard scale from 1 to 5. Combining all of the ratings, the current consensus is sitting at 1.14. A rating of 1 would be equivalent to a Strong Buy, and a rating of 5 would indicate a Strong Sell rating.
Let’s take a look at analyst target price estimates on the stock. The 6 analysts offering target price estimates on shares of Epizyme, Inc. (NASDAQ:EPZM) have set a consensus target of $23 on shares. The standard deviation of all the estimates is currently $5.549. Target price projections may differ from analyst to analyst. The lowest price target is presently $15 and the analyst with the most aggressive opinion sees the stock going to $31.
The quarterly company earnings release is usually highly anticipated. Each quarter, investors and analysts wait to see the earnings numbers when they are posted for the public. The company is slated to next publish earnings on or around 2017-08-14. The current Wall Street consensus is expecting Epizyme, Inc. (NASDAQ:EPZM) to report EPS of $-0.56 for the quarter. Analysts often update their models during the time leading up to earnings. The sentiment direction can be an important factor when trying to gauge where the Street sees the stock moving. Compared to the same quarter last year, the company reported earnings per share of $-0.49. After the most recent period, the company reported quarterly EPS of $-0.56 against the Zacks Research consensus estimate of $-0.63. This created a surprise factor of 11.11% or a numerical difference of $0.07.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell Epizyme, Inc..